Asston Pharmaceuticals Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Asston Pharmaceuticals Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹123
Per ShareLot Size
1000 Shares
Minimum Investment
₹1,23,000
Issue Size
₹27.56 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
35.06%
QIB Quota
49.81%
NII Quota
15.13%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Asston Pharmaceuticals Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
68.76%
Promoter Holding (Post-Issue)
50.66%
Issue Type
Book Building - SME
ISIN
INE0SJX01015
About the Company
Our Company is engaged in the manufacturing and export of both pharmaceutical formulations and nutraceutical products in domestic and various African and Asian markets. Presently our Company is involved in the business of manufacturing and marketing of Tablets, Capsules, Oral Liquid, External Preparations (Ointment, Cream, Gel and Lotion), and Oral Powder (Sachet, Dry Syrup) etc. Apart from manufacturing products for direct sales, our Company also manufactures various pharmaceutical products for different marketers on loan license or contract manufacturing basis. As on the date of this Red Herring Prospectus, we cater to multiple corporate clients on loan licence and/or contract manufacturing basis. Our Company basically gives contract for manufacturing the products to WHO-GMP certified contract manufacturers and FDA-accredited laboratories, ensuring adherence to industry standards from production to export. From manufacturing to exports and distributions, our Company takes responsibility and oversees each phase of the supply chain.
Industry Overview
Indian pharmaceutical industry has a strong presence at the global level. "Pharmacy of the world" as it is often called offers around 60,000 generic brands across 60 therapeutic categories, accounting for 20 per cent of global generic drug exports by volume. Not surprisingly, eight of the top 20 global generic companies are based in India. Indian pharmaceutical industry is known for its generic medicines and low-cost vaccines globally. Transformed over the years as a vibrant sector, presently Indian Pharma ranks third in pharmaceutical production by volume. The Pharmaceutical industry in India is the third largest in the world in terms of volume and 14th largest in terms of value. The Pharma sector currently contributes to around 1.72% of the country's GDP.
Company History
Our Company was originally incorporated as "Asston Pharmaceuticals Private Limited", a private limited company under Companies Act, 2013, pursuant to a certificate of incorporation dated April 16, 2019 issued by Registrar of Companies, Mumbai, Maharashtra. Thereafter, our Company was converted into a public limited company and the name of our Company was changed from "Asston Pharmaceuticals Private Limited" to "Asston Pharmaceuticals Limited" vide fresh certificate of incorporation dated August 29, 2024 issued by the Registrar of Companies, Mumbai, Maharashtra. The Corporate Identification Number of our Company is U24304MH2019PLC324187.
Products & Services
- The Company is engaged in the manufacturing and export of both pharmaceutical formulations and nutraceutical products in domestic and various African and Asian markets.
Growth Strategy
- Expanding our footprint.
- Expanding our product offerings.
- Increase our warehouse capabilities.
- Increase the numbers of contract manufacturers.
- Investment and upgradation in Information Technology (IT) and other digital initiatives.
Customer Base
Wholesaler and Retailer
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a standalone basis, as reported for FY23 to FY25.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public issue of up to 22,41,000 equity shares of face value of Rs.10/- each (the "Equity Shares") of Asston Pharmaceuticals Limited ("the Company" or "APL" or "the Issuer") at an issue price of Rs. 123 per equity share for cash, aggregating up to Rs. 27.56 crores ("Public Isue") out of which upto 1,13,000 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 123 per equity share for cash, aggregating Rs. 1.39 crores will be reserved for subscription by the market maker to the issue (the "Market Maker Reservation Portion"). The public issue less market maker reservation portion i.e. issue of upto 21,28,000 equity shares of face value of Rs. 10/- each, at an issue price of Rs. 123 per equity share for cash, aggregating upto Rs. 26.17 crores is herein after referred to as the "Net Issue". The public issue and net issue will constitute 26.33 % and 25 %, respectively of the post-issue paid-up equity share capital of the company.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Formulation Expertise.
- Experienced Promoters.
- Wide range of Products.
- Strategic Location.
- Skilled Workforce.
- The Company operates in pharmaceutical sector, which is extensively regulated, any failures on its part to comply with the existing and future statutory and/or regulatory requirements in the pharmaceutical sector could adversely affect its business, results of operations and financial condition.
- The company operate its own manufacturing facility for pharmaceutical products; however for certain products other than tablets, the company relies on third-party manufacturers to procure the pharmaceutical products.
- The company depends on the success of its relationships with the company customers. The company derives a significant part of its revenue from its major customers and the company does not have long-term contracts with these customers other than contracts with 2 customers for one year. If one or more of such customers choose not to source their requirements from it, the company business, financial condition and results of operations may be adversely affected.
- The loss of contract manufacturing tie-ups and the low entry barrier for contract manufacturing can affect production, order intake, revenue, cash flow, and profitability. The absence of exclusive agreements increases the risk of delays or disruptions in order execution, further impacting business operations.
- The company has substantial working capital expenditure and may requires additional financing to meet those requirements and have risk of receivables, which could have an adverse effect on its results of operations and financial condition.